Multiple Sclerosis and the LIF/IL-6 Axis: Use of Nanotechnology to Harness the Tolerogenic and Reparative Properties of LIF

Overview

Journal Nanobiomedicine (Rij)

Publisher Sage Publications

Specialty Biomedical Engineering

Date 2018 Jun 27

PMID 29942371

Citations 16

Authors

Su M Metcalfe

Terry B Strom

Anna Williams

Tarek M Fahmy

Affiliations

Soon will be listed here.

Abstract

Leukaemia inhibitory factor (LIF) plays a critical role in "stemness" versus "differentiation", a property that underpins the core value of LIF as a therapeutic for both the treatment of autoimmune disease and for promoting tissue repair. This value can be realized using nano-engineering technology, where a new generation of tools can, with unprecedented ability, manipulate biological functions. One striking example is the treatment of multiple sclerosis (MS). The underpinning biology is the newly identified LIF/IL-6 axis in T lymphocytes, which can tilt the behaviour between immune tolerance versus immune attack. This LIF/IL-6 axis is ideally suited to nanotherapeutic manipulation, given its inherent mechanistic simplicity of two mutually opposing feed-forward loops that determine either tolerogenic (LIF) or inflammatory (IL-6) immunity. Using LIF that is formulated in biodegradable nanoparticles (LIF-NP) and targeted to CD4+ T cells, the axis is harnessed towards immune tolerance. This has implications for the treatment of autoimmune diseases, where the clinical burden is immense. It encompasses more than 100 diseases and, in the USA alone, costs more than $100 billion in direct health care costs annually. Other properties of LIF include the promotion of healthy neuro-glial interactions within the central nervous system (CNS), where, in addition to MS, LIF-NP therapy is relevant to inflammatory neurodegenerative diseases that represent a large and increasing need within aging populations. Thirdly, LIF is a reparative growth factor that can maintain genomic plasticity. LIF-NP supports the use of stem cell-based therapies in regenerative medicine plus augment therapeutic benefits within the patient. These core properties of LIF are greatly amplified in value by the advantage of being formulated as nanoparticles, namely (i) targeted delivery, (ii) exploitation of endogenous regulatory pathways and (iii) creation of surrogate micro-stromal niches. We discuss LIF-NP as a means to harness endogenous pathways for the treatment of MS, both to reset immune self-tolerance and to promote repair of myelin that is required to support health within the nervous system.

Citing Articles

COVID-19: A systematic review and update on prevention, diagnosis, and treatment.

Aliabadi H, Eivazzadeh-Keihan R, Beig Parikhani A, Fattahi Mehraban S, Maleki A, Fereshteh S MedComm (2020). 2022; 3(1):e115.

PMID: 35281790 PMC: 8906461. DOI: 10.1002/mco2.115.

Epithelial LIF signaling limits apoptosis and lung injury during bacterial pneumonia.

Na E, Allen E, Baird L, Odom C, Korkmaz F, Shenoy A Am J Physiol Lung Cell Mol Physiol. 2022; 322(4):L550-L563.

PMID: 35137631 PMC: 8957336. DOI: 10.1152/ajplung.00325.2021.

Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects.

Abdelgawad M, Bakry N, Farghali A, Abdel-Latif A, Lotfy A Stem Cell Res Ther. 2021; 12(1):469.

PMID: 34419143 PMC: 8379570. DOI: 10.1186/s13287-021-02542-z.

Mesenchymal Stem Cells and COVID-19: Cure, Prevention, and Vaccination.

Afarid M, Sanie-Jahromi F Stem Cells Int. 2021; 2021:6666370.

PMID: 34035820 PMC: 8103964. DOI: 10.1155/2021/6666370.

Medical progress: Stem cells as a new therapeutic strategy for COVID-19.

Musial C, Gorska-Ponikowska M Stem Cell Res. 2021; 52:102239.

PMID: 33601098 PMC: 7877901. DOI: 10.1016/j.scr.2021.102239.

References

Stuart H, van Oosten A, Radzisheuskaya A, Martello G, Miller A, Dietmann S . NANOG amplifies STAT3 activation and they synergistically induce the naive pluripotent program. Curr Biol. 2014; 24(3):340-6. PMC: 3982126. DOI: 10.1016/j.cub.2013.12.040. View

Giese B, Roderburg C, Sommerauer M, Wortmann S, Metz S, Heinrich P . Dimerization of the cytokine receptors gp130 and LIFR analysed in single cells. J Cell Sci. 2005; 118(Pt 21):5129-40. DOI: 10.1242/jcs.02628. View

Almolda B, Costa M, Montoya M, Gonzalez B, Castellano B . Increase in Th17 and T-reg lymphocytes and decrease of IL22 correlate with the recovery phase of acute EAE in rat. PLoS One. 2011; 6(11):e27473. PMC: 3217052. DOI: 10.1371/journal.pone.0027473. View

Broadley S, Barnett M, Boggild M, Brew B, Butzkueven H, Heard R . Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association.... J Clin Neurosci. 2014; 21(11):1847-56. DOI: 10.1016/j.jocn.2014.01.018. View

Zhao J, Dyson S, Kriegel C, Tyers P, He X, Fahmy T . Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease. Dis Model Mech. 2014; 7(10):1193-203. PMC: 4174530. DOI: 10.1242/dmm.015859. View

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H . A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain. 1999; 122 ( Pt 12):2279-95. DOI: 10.1093/brain/122.12.2279. View

Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M . Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007; 13(10):1173-5. PMC: 5114125. DOI: 10.1038/nm1651. View

Ramsdell F, Ziegler S . FOXP3 and scurfy: how it all began. Nat Rev Immunol. 2014; 14(5):343-9. DOI: 10.1038/nri3650. View

Fontenot J, Gavin M, Rudensky A . Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4(4):330-6. DOI: 10.1038/ni904. View

10.

Gao W, Thompson L, Zhou Q, Putheti P, Fahmy T, Strom T . Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle. 2009; 8(9):1444-50. PMC: 2881570. DOI: 10.4161/cc.8.9.8348. View

11.

Boulanger M, Bankovich A, Kortemme T, Baker D, Garcia K . Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol Cell. 2003; 12(3):577-89. DOI: 10.1016/s1097-2765(03)00365-4. View

12.

Labowsky M, Fahmy T . Diffusive transfer between two intensely interacting cells with limited surface kinetics. Chem Eng Sci. 2012; 74:114-123. PMC: 3319135. DOI: 10.1016/j.ces.2012.02.001. View

13.

Tosi G, Fano R, Bondioli L, Badiali L, Benassi R, Rivasi F . Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine (Lond). 2011; 6(3):423-36. DOI: 10.2217/nnm.11.11. View

14.

Ivanov I, McKenzie B, Zhou L, Tadokoro C, Lepelley A, Lafaille J . The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006; 126(6):1121-33. DOI: 10.1016/j.cell.2006.07.035. View

15.

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

16.

Metcalfe S . Axotrophin and leukaemia inhibitory factor (LIF) in transplantation tolerance. Philos Trans R Soc Lond B Biol Sci. 2005; 360(1461):1687-94. PMC: 1569543. DOI: 10.1098/rstb.2005.1697. View

17.

Cobbold S, Nolan K, Graca L, Castejon R, Le Moine A, Frewin M . Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms. Immunol Rev. 2003; 196:109-24. DOI: 10.1046/j.1600-065x.2003.00078.x. View

18.

Steenblock E, Fahmy T . A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol Ther. 2008; 16(4):765-72. DOI: 10.1038/mt.2008.11. View

19.

Metcalfe S, Fahmy T . Targeted nanotherapy for induction of therapeutic immune responses. Trends Mol Med. 2011; 18(2):72-80. DOI: 10.1016/j.molmed.2011.11.002. View

20.

Wang X, Kimbrel E, Ijichi K, Paul D, Lazorchak A, Chu J . Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Reports. 2014; 3(1):115-30. PMC: 4110787. DOI: 10.1016/j.stemcr.2014.04.020. View